To find out if the shortening of the ester group-bearing the hydrophobic side-chain of PG3-Oc will reduce its anticancer activity, cell viability assays were performed using cancer cell lines with p53 mutation R273H (HT29), p53 mutation R175H (TOV-112D), isogenic cell lines HCT116 (wt, p53-null and p53 R175H) and two normal cell lines HFF-1 (human foreskin fibroblast cell with wild-type p53) and MRC5 (human lung fibroblast cell with wild-type p53). Here, TP53 is linked to cancer.